Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Sabadell – page 10

295 clinical trials in Sabadell, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Sabadell at a glance
295
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

295 trials in Sabadell

Open in trial search

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Neoplasm

Recruiting

Study on the Safety and Effectiveness of ART0380 Alone or with Gemcitabine or Irinotecan for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ART0380 mesilate
  • Sponsor:Artios Pharma Limited

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Ovarian cancer

Not yet recruiting

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Acromegaly

Not yet recruiting

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pasireotide
  • Sponsor:Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Infertility+1

Not yet recruiting

Effect of Follitropin Delta plus Menotrophin on Embryo Quality in Advanced Age Women with Infertility

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Delta
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Clear cell renal cell carcinoma

Not yet recruiting

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Vall D Hebron Institute Of Oncology

Axial spondyloarthritis+1

Not yet recruiting

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Care Arthritis Ltd.

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Sabadell

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Acute Respiratory Distress Syndrome (ARDS) and advanced lung cancer treatments. Studies evaluating new therapeutic approaches for non-small cell lung cancer, including combination therapies with immunotherapy agents.

  • Mechanical ventilation optimization
  • Combined immunotherapy approaches
  • Advanced stage cancer treatment
02 Oncology Studies

Comprehensive research into various cancer types, including bladder cancer and prostate cancer. Studies examining novel combination therapies and investigating new treatment approaches for both early-stage and metastatic conditions.

  • Immunotherapy combinations
  • Targeted therapies
  • Treatment resistance
03 Autoimmune Conditions

Groundbreaking research in autoimmune disorders including Sjögren's Syndrome and Systemic Sclerosis. Studies evaluating novel biological therapies and investigating long-term treatment outcomes for chronic conditions.

  • Biological therapy assessment
  • Long-term safety evaluation
  • Quality of life improvements
Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.